Providers who offer stem cell procedures that are not FDA approved must prominently display a notice and provide patients with a written statement with that information, in today's bite-sized hospital and health industry news from California, Ohio, and Wisconsin.
Cigna announced that beginning in 2018 it will no longer cover Purdue Pharma's OxyContin as a preferred option for customers enrolled in employer-based health plans—but some industry experts say the move is unlikely to have a significant effect on the opioid misuse epidemic.
Sidewalk Labs—an urban innovation organization held under Google parent company Alphabet—has launched a new health care startup to provide affordable preventive health care to Medicaid and lower-income Medicare beneficiaries.
FDA Commissioner Scott Gottlieb says some of the medicines produced on the island "are critical to Americans" and that a "loss of access could have significant public health consequences."
Hollywood, Health & Society has unveiled the 2017 winners of the Sentinel Awards, which recognize television programs that depict "exemplary storylines" regarding health, safety, and security.
Borgess Medical Group launched an initiative to curb the rate of patients with uncontrolled diabetes by 20 percent in fewer than 90 days—and not only did the medical group exceed its target, but its success spurred Ascension Health Michigan to adopt similar goals, Mike Miliard writes for Healthcare IT News.
